Your browser doesn't support javascript.
loading
Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme, Pierre; Leroux-Roels, Geert; Simon, Philippe; Foidart, Jean-Michel; Donders, Gilbert; Hoppenbrouwers, Karel; Levin, Myron; Tibaldi, Fabian; Poncelet, Sylviane; Moris, Philippe; Dessy, Francis; Giannini, Sandra L; Descamps, Dominique; Dubin, Gary.
  • Van Damme P; Universiteit Antwerpen, Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, Building R, 2nd Floor, Universiteitsplein 1, 2610 Antwerpen, Belgium. Electronic address: pierre.vandamme@ua.ac.be.
  • Leroux-Roels G; Center for Vaccinology, Ghent University and Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Electronic address: geert.lerouxroels@ugent.be.
  • Simon P; Service de Gynécologie Obstétrique, Hôpital Erasme, Route de Lennik 808, 1070 Bruxelles, Belgium. Electronic address: philippe.simon@erasme.ulb.ac.be.
  • Foidart JM; CHR Citadelle, Service de Gynécologie Obstétrique, Boulevard du 12ieme de Ligne 1, 4000 Liège, Belgium. Electronic address: jmfoidart@ulg.ac.be.
  • Donders G; Gynaecologie, Heilig Hartziekenhuis, Kliniekstraat 45, 3300 Tienen, Belgium. Electronic address: gilbert.donders@femicare.net.
  • Hoppenbrouwers K; KULeuven, Jeugdgezondheidszorg, Kapucijnvoer 35/1, 3000 Leuven, Belgium. Electronic address: karel.hoppenbrouwers@med.kuleuven.be.
  • Levin M; University of Colorado School of Medicine, Building 401, 1784 Racine St., Aurora, CO 80045, USA. Electronic address: Myron.Levin@ucdenver.edu.
  • Tibaldi F; GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: fabian.s.tibaldi@gsk.com.
  • Poncelet S; GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: sylviane.poncelet@gsk.com.
  • Moris P; GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: philippe.moris@gsk.com.
  • Dessy F; GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: francis.dessy@gsk.com.
  • Giannini SL; GlaxoSmithKline Vaccines, Rue de l'Institut 89, 1330 Rixensart, Belgium. Electronic address: sandra.giannini@gsk.com.
  • Descamps D; GlaxoSmithKline Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: dominique.descamps@gsk.com.
  • Dubin G; GlaxoSmithKline SA, 2301 Renaissance Boulevard, RN0220, King of Prussia, PA 19406, USA. Electronic address: Gary.O.Dubin@gsk.com.
Vaccine ; 32(29): 3694-705, 2014 Jun 17.
Article en En | MEDLINE | ID: mdl-24674663
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Infecciones por Papillomavirus / Vacunas contra Papillomavirus / Formación de Anticuerpos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans País como asunto: America do norte / Europa Idioma: En Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Infecciones por Papillomavirus / Vacunas contra Papillomavirus / Formación de Anticuerpos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Female / Humans País como asunto: America do norte / Europa Idioma: En Año: 2014 Tipo del documento: Article